The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Single Nucleotide Polymorphism (SNP) Genotyping Market During 2026–2030?
The single nucleotide polymorphism (snp) genotyping market has seen rapid growth in its size over recent years. It is forecast to increase from $12.34 billion in 2025 to $14.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.1%. This historical expansion can be linked to factors such as limited early-stage genotyping capabilities, increasing demand within research, the significant cost of genomic analysis, a rise in collaborations between research laboratories, and its initial use in pharmacogenomics.
The single nucleotide polymorphism (snp) genotyping market is projected to experience substantial expansion in the coming years. This market is forecast to reach a valuation of $29.74 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 19.3%. Key drivers for this anticipated growth include the emergence of high-throughput SNP platforms, broader uptake in personalized medicine, the incorporation of AI for predictive analysis, its increasing use in clinical diagnostics, and the expanding applications within agricultural genomics. Notable trends expected during this forecast period encompass its integration with pharmacogenomics, advancements in disease risk prediction, augmented application in agriculture and animal breeding, the increasing embrace of microarray-based genotyping, and the proliferation of point-of-care SNP testing.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12569&type=smp
What Drivers Are Expected To Influence The Single Nucleotide Polymorphism (SNP) Genotyping Market During The Forecast Period?
The escalating prevalence of chronic health conditions is anticipated to stimulate the expansion of the single nucleotide polymorphism (SNP) genotyping market in the foreseeable future. Chronic conditions are long-term health issues that persist for a year or longer, necessitating continuous medical management, restricting daily routines, or both. The growing incidence of these chronic diseases underscores the vital role of single-nucleotide polymorphism (SNP) genotyping in uncovering genetic predispositions and advancing personalized medical approaches. For instance, in April 2025, information from the Centers for Disease Control and Prevention (CDC), a US-based federal agency, indicated that in 2023, approximately 194 million U.S. adults, representing 76.4% of the adult population, reported having at least one chronic condition. The prevalence of such conditions was notably 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the increasing burden posed by chronic conditions is a key driver for the growth of the single nucleotide polymorphism (SNP) genotyping systems market.
How Are The Various Segments Of The Single Nucleotide Polymorphism (SNP) Genotyping Market Categorized?
The single nucleotide polymorphism (snp) genotyping market covered in this report is segmented –
1) By Product: Consumables, Instruments, Services
2) By Technology: TaqMan SNP Genotyping, Mass Array SNP Genotyping, SNP Gene Chip Arrays, Other Technologies
3) By Application: Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals And Pharmacogenomics, Agricultural Biotechnology, Other Applications
Subsegments:
1) By Consumables: Reagents And Kits, DNA Probes, Microarrays
2) By Instruments: SNP Genotyping Platforms, Sequencers, PCR Machines
3) By Services: SNP Genotyping Services, Data Analysis Services, Consultation Services
Which Market Trends Are Creating New Opportunities In The Single Nucleotide Polymorphism (SNP) Genotyping Market?
Major companies in the single nucleotide polymorphism (SNP) genotyping market are developing biomarkers for coronary heart disease detection to enhance their market profitability. Single nucleotide polymorphism (SNP) biomarkers pertinent to coronary heart disease (CHD) detection are specific genetic variations identified through genomic research, linked to an increased risk or susceptibility to coronary heart disease. For instance, in February 2023, Cardio Diagnostics, a US-based biotechnology company, launched PrecisionCHD. PrecisionCHD is an AI-driven blood test that uses a combination of epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers to identify CHD. The test employs a machine-learning model to achieve over 75% sensitivity for both genders, offering a non-invasive option for collecting blood samples in-office or at home. This eliminates the necessity for traditional tests like stress tests, ensuring objectivity by relying solely on biomarkers, rather than self-reported patient data.
Which Major Firms Influence Developments In The Single Nucleotide Polymorphism (SNP) Genotyping Market?
Major companies operating in the single nucleotide polymorphism (snp) genotyping market are Thermo Fischer Scientific Inc, Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc, Eurofins Genomics LLC, Beckman Coulter Inc, Bio-Rad Laboratories Inc, Qiagen N.V, Sigma-Aldrich Corporation, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc, LGC Ltd, Sequenom Inc, Fluidigm Corporation, Oxford Gene Technology, Affymetrix Inc, PREMIER Biosoft International Inc, Rubicon Genomics, Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc
Read the full single nucleotide polymorphism (snp) genotyping market report here:
Which Region Is Forecast To Lead The Single Nucleotide Polymorphism (SNP) Genotyping Market In Terms Of Market Size?
North America was the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (snp) genotyping market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Single Nucleotide Polymorphism (SNP) Genotyping Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12569&type=smp
Browse Through More Reports Similar to the Global Single Nucleotide Polymorphism (SNP) Genotyping Market 2026, By The Business Research Company
Genotyping Global Market Report
https://www.thebusinessresearchcompany.com/report/genotyping-global-market-report
Genotyping Assay Global Market Report
https://www.thebusinessresearchcompany.com/report/genotyping-assay-global-market-report
Genomics Global Market Report
https://www.thebusinessresearchcompany.com/report/genomics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model